secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108413
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Q2 net loss $31.2M; pauses IV SMARCA2 degrader, focuses on oral PRT7732
--------------------------------------------------------------------------------

- Net loss of $31.2M ($0.41 per share) improved from $34.7M ($0.46) in Q2 2024.
- Cash, equivalents and marketable securities $77.3M; runway into Q2 2026.
- PRT3789 (IV) Phase 1 completed; will only advance with partnership. Oral PRT7732 enrolling 7th cohort (125 mg once daily); initial data by year-end 2025.
- KAT6A degrader development candidate selected; IND on track for H1 2026.
- R&D expense $25.8M (down from $29.5M); G&A $6.4M (down from $7.7M) YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025108413/0000950170-25-108413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025108413/prld-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer